Company Filing History:
Years Active: 2018-2025
Title: Innovator in Cancer Therapy - Matthew J. Frigault
Introduction
Matthew J. Frigault, an accomplished inventor based in Philadelphia, PA, has made significant contributions to the field of cancer therapy through his innovative work on T cell therapies. With a total of four patents to his name, Frigault's research is paving the way for new treatment methodologies that can improve patient outcomes in oncology.
Latest Patents
Among Frigault's latest patents is a groundbreaking invention titled "Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer." This invention provides compositions and methods for the generation of genetically modified T cells that comprise a chimeric antigen receptor (CAR). The CAR includes an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. Notably, these T cells exhibit prolonged exponential expansion in culture that is ligand-independent and does not rely on the addition of exogenous cytokines or feeder cells.
Career Highlights
Matthew J. Frigault is currently affiliated with the University of Pennsylvania, where he leverages his expertise in immunology and cellular therapy to enhance cancer treatment protocols. His role at this esteemed institution places him in the midst of leading-edge research, contributing to advancements that have the potential to revolutionize therapies for cancer patients.
Collaborations
In his pursuit of innovative cancer treatments, Frigault collaborates with notable colleagues, including Yangbing Zhao and John Scholler. These partnerships are vital in driving forward the research that underpins Frigault’s patents and broaden the scope of discoveries in T cell therapies.
Conclusion
Matthew J. Frigault is a visionary in the realm of cancer treatment, dedicating his career to the development of innovative therapeutic solutions. His contributions through patent work not only highlight his inventiveness but also underscore the importance of collaboration in scientific discovery. As he continues his impactful research at the University of Pennsylvania, the future of cancer therapy looks promising with pioneers like Frigault leading the charge.